IsoRay Inc - Entwickler von isotopbasierten Medizinprodukten (Seite 2)

[Crowww]

Glückwunsch Edelweiss 😍

[Edelweiss70]

Antwort auf Beitrag Nr.: 75.496.794 von Edelweiss70 am 21.03.24 18:49:31

Fast auf Tageshoch bei neuem 52Wochen Hoch geschlossen.
Stabil 💪

[Edelweiss70]

Antwort auf Beitrag Nr.: 75.473.016 von Edelweiss70 am 18.03.24 13:46:24

So langsam geht ‘r d’r Peeeter 🐿.

[Edelweiss70]

Antwort auf Beitrag Nr.: 75.473.007 von Edelweiss70 am 18.03.24 13:45:41

Der Kurs zieht vorbörslich ja schon ganz gut an , mal sehen was da geht

[Edelweiss70]

Antwort auf Beitrag Nr.: 75.433.719 von Edelweiss70 am 11.03.24 18:26:28

Globenewswire
18.3.24
Full article

„SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.

Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study. „

[Edelweiss70]

globalnewswire 11.3.24

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here.

The event will feature presentations from the following members of the Company’s management:

Thijs Spoor, Chief Executive Officer
Michael K. Schultz, PhD, Chief Science Officer
Markus Puhlman, MD, Chief Medical Officer
In addition, key opinion leader Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) will provide an overview of the use of specialized targeting peptides and personalized alpha-particle radiopharmaceuticals such as 212Pb to diagnose tumors and deliver powerful radiation specifically to cancer cells.

The event will highlight the Company's theranostic approach and proprietary technology, including the development of complementary imaging diagnostics that enable the ability to see the specific tumor and then treat it, to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.

A live question and answer session will follow the formal presentations.

About Richard L. Wahl, MD
Richard L. Wahl, MD, is a professor at Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis and served as the director of MIR from 2014 to 2023. An alumnus, Wahl completed a diagnostic radiology residency and nuclear medicine fellowship at MIR. Prior to being named director at MIR, he was director of the Division of Nuclear Medicine at Johns Hopkins University and the first recipient of the Henry N. Wagner Jr. Professorship.

Wahl is a leader in the use of PET scans to diagnose human cancers and other diseases and was among the first to harness the power of the immune system to precisely target radiation therapy to cancers, a technique that has become known as radioimmunotherapy. He has been at the forefront of efforts to combine quantitative data from multiple kinds of scans to form so-called fusion images that can help physicians more precisely diagnose and characterize cancers.
Wahl has received numerous awards, including the 2018 Georg Charles de Hevesy Award from the Society of Nuclear Medicine and Molecular Imaging, where he served as president. He is an elected member of the American Society for Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. A fellow of the American College of Radiology, Wahl holds 18 radiology patents and has published more than 450 peer-reviewed scientific manuscripts. He completed a research fellowship in immunology and earned his medical degree from Washington University in St. Louis.

[Edelweiss70]

Antwort auf Beitrag Nr.: 75.398.111 von Edelweiss70 am 05.03.24 16:01:54

Wäre doch mal ein schöner Wochenabschluss über 1,10$

[Edelweiss70]

Hier wächst ja nun augenscheinlich etwas und ich würde mir nun mal eine Meldung zu einem Auftrag aus dem Pharma oder Militärsektor wünschen. Die Möglichkeiten können mannigfaltiger beinahe nicht sein.

[Edelweiss70]

News ALert !!!!!!!!!!


SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) --



Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.
Previously operated by Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company, this 11,500 square foot facility, located in Somerset, New Jersey, has operated in compliance with both Part 212 and Part 211 of Title 21 of the Code of Federal Regulations (CFR) in the U.S., meeting Current Good Manufacturing Practice (cGMP) requirements. As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies (TAT). Moreover, with its three cGMP suites at the facility, Perspective expects to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S.

The facility acquisition is part of a series of strategic agreements with Lantheus that Perspective announced on January 9, 2024, which included an initial equity investment in Perspective. In addition, on March 4, 2024, Perspective announced it had entered into an investment agreement to sell shares of the Company’s common stock to certain accredited institutional investors for gross proceeds of $87.4 million, $57.4 million of which will be purchased by Lantheus upon the consummation of the transaction.

“We look forward to welcoming the exceptional talent at this facility and integrating them into our team,” said Shane Cobb, Executive Vice President of Operations, Perspective Therapeutics. “The acquisition of this facility much earlier than initially planned is expected to allow us to move forward more quickly to deliver clinical and, if approved for commercialization, commercial doses. Given the 10.6-hour half-life for 212Pb lead, it is important that we have the infrastructure and personnel to support production of our radiopharmaceuticals, all within the vicinity of the patients we hope to impact. This is a significant milestone for Perspective as we build upon the progress we have made in establishing clinical manufacturing.”

“We are thrilled to expand our manufacturing and supply chain infrastructure to include this facility capable of operating in compliance with Parts 212 and 211,” said Thijs Spoor, Chief Executive Officer, Perspective Therapeutics. “The acquisition is a testament to our commitment to making our targeted alpha-particle therapies available to patients in critical need, and builds on our strategic expansion as we look to establish facilities in proximity to major treatment hubs in the U.S.”

“We are excited for the opportunity to strengthen our strategic collaboration with Perspective Therapeutics,” said Brian Markison, Chief Executive Officer, Lantheus. “We recognize the transformative potential of Perspective’s alpha therapies and platform which we believe have the potential to improve efficacy, while minimizing toxicity across a range of tumor settings. We are pleased the Somerset facility will be used to manufacture these innovative product candidates.”

About Part 211 and Part 212
Part 211 of Title 21 of the Code of Federal Regulations (CFR) outlines the Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceutical products. It covers various aspects of pharmaceutical manufacturing, including facilities, equipment, controls, and processes to ensure the quality and safety of the final products. Part 212 of Title 21 of the CFR specifically pertains to the cGMP requirements for the manufacturing of positron emission tomography (PET) drugs. PET drugs are radiopharmaceuticals used in medical imaging, and Part 212 sets forth requirements tailored to their unique production processes and quality control measures. The main difference between Part 211 and Part 212 lies in their focus areas, with Part 212 catering to the specialized needs of PET drug manufacturing. Like drugs used for PET, Perspective anticipates that its 203Pb-labelled peptides will be regulated under Part 212. Like other manufactured drugs, Perspective anticipates that 212Pb-labelled peptides will be regulated under Part 211.

[Edelweiss70]

Na da könnte sich doch was tun......



Übersetzung ins Deutsche(ohne Gewähr)

Perspective Therapeutics, Inc. („Perspective“ oder „das Unternehmen“) (NYSE AMERICAN: CATX), ein radiopharmazeutisches Unternehmen, das fortschrittliche Behandlungsanwendungen für Krebserkrankungen im gesamten Körper entwickelt, gab heute bekannt, dass es eine Investitionsvereinbarung mit einem ausgewählten Unternehmen abgeschlossen hat Gruppe institutioneller akkreditierter Anleger, Wertpapiere im Rahmen einer Privatplatzierung für einen Gesamtbruttoerlös von etwa 87,4 Millionen US-Dollar zu verkaufen, vor Abzug der Gebühren der Platzierungsstelle und anderer Angebotskosten.
Im Rahmen der Privatplatzierung verkauft das Unternehmen 92.009.981 Stammaktien zu einem Preis von 0,95 US-Dollar pro Aktie, was dem Schlusskurs pro Stammaktie des Unternehmens an der NYSE American am 1. März 2024 entspricht. Die Privatplatzierung wird erwartet Abschluss am 6. März 2024, vorbehaltlich der Erfüllung der üblichen Abschlussbedingungen.
Oppenheimer & Co. fungiert als Lead Placement Agent für die Privatplatzierung. B. Riley Securities fungiert als Platzierungsagent und JonesTrading Institutional Services LLC und LifeSci Capital fungieren als Co-Placement-Agenten für die Privatplatzierung.

Perspective beabsichtigt, den Nettoerlös für allgemeine Unternehmens- und Betriebskapitalzwecke zu verwenden, wozu Forschungs- und Entwicklungsausgaben, Ausgaben für präklinische Studien und klinische Studien, Herstellungsausgaben, Kommerzialisierungsausgaben, Kapitalausgaben, Akquisitionen neuer Technologien, Produkte oder Unternehmen und Investitionen gehören können.

Die im Rahmen der Privatplatzierung zu verkaufenden Stammaktien wurden nicht gemäß dem Securities Act von 1933 in der jeweils gültigen Fassung (der „Securities Act“) oder den Wertpapiergesetzen eines Staates oder einer anderen anwendbaren Gerichtsbarkeit registriert und dürfen nicht angeboten oder verkauft werden in den Vereinigten Staaten ohne Registrierung oder eine anwendbare Ausnahme von den Registrierungsanforderungen des Securities Act und den Wertpapiergesetzen der anwendbaren Bundesstaaten oder anderen Gerichtsbarkeiten. Das Unternehmen hat zugestimmt, bei der U.S. Securities and Exchange Commission (die „SEC“) eine Registrierungserklärung einzureichen, in der der Weiterverkauf der im Rahmen der Privatplatzierung ausgegebenen Stammaktien innerhalb eines bestimmten Zeitraums nach Abschluss der Privatplatzierung registriert wird.
Die im Rahmen der Privatplatzierung zu verkaufenden Stammaktien wurden nicht gemäß dem Securities Act von 1933 in der jeweils gültigen Fassung (der „Securities Act“) oder den Wertpapiergesetzen eines Staates oder einer anderen anwendbaren Gerichtsbarkeit registriert und dürfen nicht angeboten oder verkauft werden in den Vereinigten Staaten ohne Registrierung oder eine anwendbare Ausnahme von den Registrierungsanforderungen des Securities Act und den Wertpapiergesetzen der anwendbaren Bundesstaaten oder anderen Gerichtsbarkeiten. Das Unternehmen hat zugestimmt, eine Registrierungserklärung bei der U.S. Securities and Exchange Commission (die „SEC“) einzureichen, in der der Weiterverkauf der ausgegebenen Stammaktien